Bide Pharmatech Co., Ltd. (SHA:688073)
China
· Delayed Price · Currency is CNY 56.66
-0.95 (-1.65%)
Mar 9, 2026, 4:00 PM EDT
Bide Pharmatech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Operating Revenue | 1,324 | 1,102 | 1,092 | 833.8 | 606.05 | Upgrade
|
| Other Revenue | - | 0.01 | 0.03 | 0.03 | 0.17 | Upgrade
|
| Revenue | 1,324 | 1,102 | 1,092 | 833.83 | 606.22 | Upgrade
|
| Revenue Growth (YoY) | 20.13% | 0.93% | 30.95% | 37.55% | 54.86% | Upgrade
|
| Cost of Revenue | - | 680.35 | 673.38 | 471.29 | 315.89 | Upgrade
|
| Gross Profit | 1,324 | 421.66 | 418.48 | 362.54 | 290.33 | Upgrade
|
| Selling, General & Admin | - | 244.87 | 250.12 | 167.26 | 145.16 | Upgrade
|
| Research & Development | - | 55.62 | 59.72 | 43.46 | 32.1 | Upgrade
|
| Other Operating Expenses | 1,126 | 6.71 | 5.01 | 3.96 | 2.42 | Upgrade
|
| Operating Expenses | 1,126 | 308.96 | 319.18 | 218.2 | 182.75 | Upgrade
|
| Operating Income | 197.5 | 112.71 | 99.3 | 144.34 | 107.58 | Upgrade
|
| Interest Expense | - | -3.32 | -2.53 | -2.16 | -0.92 | Upgrade
|
| Interest & Investment Income | - | 23.74 | 31.74 | 8.86 | 3.9 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 4.99 | 5.93 | 12.55 | -6.67 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.54 | -4.12 | -2.5 | -2.23 | -1.08 | Upgrade
|
| EBT Excluding Unusual Items | 195.96 | 134 | 131.95 | 161.35 | 102.8 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 3.15 | -12.63 | -0.46 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 1.15 | 0.44 | - | 7.92 | Upgrade
|
| Asset Writedown | - | -0.03 | -0 | -0 | -0.04 | Upgrade
|
| Other Unusual Items | - | 9.74 | 6.25 | 10.88 | 3.87 | Upgrade
|
| Pretax Income | 195.96 | 148.02 | 126 | 171.77 | 114.56 | Upgrade
|
| Income Tax Expense | 43.75 | 30.59 | 17.55 | 25.8 | 16.99 | Upgrade
|
| Earnings From Continuing Operations | 152.2 | 117.43 | 108.45 | 145.97 | 97.57 | Upgrade
|
| Minority Interest in Earnings | - | - | 1.13 | - | - | Upgrade
|
| Net Income | 152.2 | 117.43 | 109.57 | 145.97 | 97.57 | Upgrade
|
| Net Income to Common | 152.2 | 117.43 | 109.57 | 145.97 | 97.57 | Upgrade
|
| Net Income Growth | 29.61% | 7.17% | -24.94% | 49.60% | 65.37% | Upgrade
|
| Shares Outstanding (Basic) | 87 | 89 | 91 | 74 | 67 | Upgrade
|
| Shares Outstanding (Diluted) | 87 | 89 | 91 | 74 | 67 | Upgrade
|
| Shares Change (YoY) | -2.23% | -1.76% | 22.83% | 10.09% | 8.03% | Upgrade
|
| EPS (Basic) | 1.75 | 1.32 | 1.21 | 1.98 | 1.46 | Upgrade
|
| EPS (Diluted) | 1.75 | 1.32 | 1.21 | 1.98 | 1.46 | Upgrade
|
| EPS Growth | 32.58% | 9.09% | -38.89% | 35.89% | 53.38% | Upgrade
|
| Free Cash Flow | - | 69.97 | -118.47 | -8.54 | -94.09 | Upgrade
|
| Free Cash Flow Per Share | - | 0.79 | -1.31 | -0.12 | -1.41 | Upgrade
|
| Dividend Per Share | - | 0.900 | 0.900 | 1.100 | - | Upgrade
|
| Dividend Growth | - | - | -18.18% | - | - | Upgrade
|
| Gross Margin | 100.00% | 38.26% | 38.33% | 43.48% | 47.89% | Upgrade
|
| Operating Margin | 14.92% | 10.23% | 9.09% | 17.31% | 17.75% | Upgrade
|
| Profit Margin | 11.50% | 10.66% | 10.04% | 17.51% | 16.10% | Upgrade
|
| Free Cash Flow Margin | - | 6.35% | -10.85% | -1.02% | -15.52% | Upgrade
|
| EBITDA | 208.37 | 123.58 | 108.85 | 150.15 | 111.51 | Upgrade
|
| EBITDA Margin | 15.74% | 11.21% | 9.97% | 18.01% | 18.39% | Upgrade
|
| D&A For EBITDA | 10.87 | 10.87 | 9.55 | 5.81 | 3.93 | Upgrade
|
| EBIT | 197.5 | 112.71 | 99.3 | 144.34 | 107.58 | Upgrade
|
| EBIT Margin | 14.92% | 10.23% | 9.09% | 17.31% | 17.75% | Upgrade
|
| Effective Tax Rate | 22.33% | 20.67% | 13.93% | 15.02% | 14.83% | Upgrade
|
| Revenue as Reported | - | 1,102 | 1,092 | 833.83 | 606.22 | Upgrade
|
| Advertising Expenses | - | 9.59 | 7.77 | 5.65 | 5.87 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.